Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M. Domchek, Bella Kaufman, Ayala Hubert et al.|Gynecologic Oncology|2015Cited by 300
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumoursNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Annals of Oncology|2021Cited by 10
Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Cancer Research|2024Cited by 3
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trialZulfa Omer, Wojciech Jurczak, Alexey V. Danilov et al.|Blood|2025Cited by 3
POSTER: CLL-563 Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings From an Ongoing Phase 1a StudyZulfa Omer, Talha Munir, Alexey V. Danilov et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0